Drug-Eluting Stent with Ultrathin, Bioresorbable Polymer Bests Current Standard Device

A lower rate of target-lesion failure at 1 year occurred with the newer stent.

Stents with the theoretical advantages of thinner struts and bioresorbable polymers (used for drug delivery) have been developed but, to date, have not been shown to be superior to current-generation durable-polymer drug-eluting stents (DES). In a multicenter trial (BIOFLOW V; NCT02389946), researchers randomized 1334 patients to receive, in a 2:1 ratio, either a bioresorbable, thin-strut (60-µm) polymer sirolimus-eluting stent (SES; Orsiro, Biotronik) or a durable-polymer 81-µm-strut everolimus-eluting stent (EES; Xience, Abbott Vascular). Biotronik funded the study.

Incidence of the primary endpoint — target-lesion failure at 12 months — was 6% in the SES group and 10% in the EES group (95% confidence interval, –6.8 to –0.3: P=0.04), with …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)